Scholarlink

<p>Succinoglycan riclin (RIC), a natural polysaccharide with diverse biological activities, was employed as a drug carrier to construct a novel nanoplatform. Polysaccharide-Pt(IV) conjugates were synthesized via esterification between the hydroxyl groups of RIC and a Pt(IV) prodrug, which was subsequently loaded with resveratrol (RES) to form the RES@RIC-Pt(IV) nanoplatform. The successful synthesis and physical properties of the complex were confirmed through multiple characterization techniques. Pt(IV) was significantly bonded to the polysaccharide chain. The drug loading capacities for platinum and RES were quantified using ICP-OES and UV–Vis spectrophotometry, respectively.&#xa0;The percentage of Pt content in RIC-Pt (IV) conjugates can be calculated as 11.71%. In vitro cytotoxicity assays revealed that the RES@RIC-Pt(IV) platform exhibited significantly enhanced toxicity against HepG2 and LO2 cancer cell lines compared to individual small-molecule drugs. These results demonstrate that this multi-drug delivery system achieves a potent synergistic anticancer effect, highlighting its potential for improved cancer therapy.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Construction of succinoglycan riclin-Pt (IV) conjugates for carrying resveratrol: a potential tool for biomedical applications

  • 期刊论文

  • 发表日期：

    2026年1月26日

查看全文
  • Hongmei Zhang,
  • Pengge Wang,
  • Yunxia Yang,
  • Daliang Zhu,
  • Yanqing Wang

摘要

Succinoglycan riclin (RIC), a natural polysaccharide with diverse biological activities, was employed as a drug carrier to construct a novel nanoplatform. Polysaccharide-Pt(IV) conjugates were synthesized via esterification between the hydroxyl groups of RIC and a Pt(IV) prodrug, which was subsequently loaded with resveratrol (RES) to form the RES@RIC-Pt(IV) nanoplatform. The successful synthesis and physical properties of the complex were confirmed through multiple characterization techniques. Pt(IV) was significantly bonded to the polysaccharide chain. The drug loading capacities for platinum and RES were quantified using ICP-OES and UV–Vis spectrophotometry, respectively. The percentage of Pt content in RIC-Pt (IV) conjugates can be calculated as 11.71%. In vitro cytotoxicity assays revealed that the RES@RIC-Pt(IV) platform exhibited significantly enhanced toxicity against HepG2 and LO2 cancer cell lines compared to individual small-molecule drugs. These results demonstrate that this multi-drug delivery system achieves a potent synergistic anticancer effect, highlighting its potential for improved cancer therapy.

Graphical abstract